AstraZeneca and Bristol Myers Squibb have held talks in recent months about a potential merger that could create a company valued at nearly $400 billion. For shareholders, that puts two large drug makers on the same valuation path while Monday's open becomes the first test of how the market prices the odds.
$400 billion is the scale the combination could reach if the talks produce a deal, with AstraZeneca's roughly $264 billion market value and Bristol Myers Squibb's roughly $133 billion adding up to that neighborhood. The companies did not provide comments or share a statement, and no deal structure has been disclosed.
Pascal Soriot and Pfizer in
Under CEO Pascal Soriot, AstraZeneca rebuffed a $118 billion takeover approach from Pfizer in 2014. Its share price has more than quadrupled since then, and the company has since announced a $50 billion U.S. manufacturing and R&D investment commitment plus plans for a direct U.S. listing.
Friday's close left AstraZeneca's NYSE-listed shares at $169.64, down $1.70 on the day and more than $40 below their 52-week high of $212.71. Bristol Myers Squibb ended at $65.31, a whisker from its 52-week high of $65.66, after trading on above-average volume of 14.58 million shares.
Bristol Myers Squibb at $12.97 billion
$12.97 billion in Q2 2026 revenue and $2.04 in EPS gave Bristol Myers Squibb a clean beat against consensus for EPS of $1.61 and revenue of $11.71 billion. AstraZeneca also beat on profit, with Q2 EPS of $2.63 against a $2.48 estimate, even as revenue of $15.38 billion came in just below consensus of $15.45 billion on July 27.
11% lower GAAP R&D spending, at about $10 billion in 2025, shows why Bristol Myers Squibb has been pushing acquisitions and partnership agreements with BioNTech and Hengrui Pharma to refill its pipeline. A cross-border combination of this size would draw review from the Federal Trade Commission, the UK Competition and Markets Authority, and the European Commission at the same time.
October 29 and October 30
October 29 brings Bristol Myers Squibb's Q3 2026 results, with consensus for EPS of $1.61 on revenue of $12.04 billion, followed by AstraZeneca on October 30 with consensus for EPS of $2.63 on revenue of $16.06 billion. If the talks hold together, those results and Monday's open will give the first hard read on whether the market is pricing a merger that could reshape both balance sheets.
The Financial Times said the talks could be delayed or fall apart entirely, which leaves one question in front of both stocks: what deal structure, if any, are AstraZeneca PLC and Bristol-Myers Squibb Company considering?
